Table 2

- Association of MTHFD1 levels with clinical indications for small cell lung cancer, lung squamous cell carcinoma and lung adenocarcinoma patients.

VariablesSCLC (n=70)LUSC (n=56)LUAD (n=70)
MTHFD1 high (n=31)MTHFD1 low (n=39)P-valuesMTHFD1 high (n=22)MTHFD1 low (n=34)P-valuesMTHFD1 high (n=25)MTHFD1 low (n=45)P-values
T stage
1-29 (29.0)25 (64.1)0.0039 (40.9)20 (50.8)0.1908 (32.0)25 (55.6)0.058
3-422 (71.0)14 (35.9)13 (59.1)14 (41.2)17 (68.0)20 (44.4)
Metastases
LM
Yes25 (80.6)27 (69.2)0.27818 (81.8)26 (76.5)0.63420 (80.0)29 (64.4)0.173
No6 (19.4)12 (30.8)4 (18.2)8 (23.5)5 (20.0)16 (35.1)
DM
Yes20 (64.5)15 (38.5)0.03014 (63.6)13 (38.2)0.06315 (60.0)19 (42.2)0.154
No11 (35.5)24 (61.5)8 (36.4)21 (61.8)10 (40.0)26 (57.8)

Values are presented as numbers and percentages (%). LC: lung cancer, LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, SCLC: small cell lung cancer, LM: lymphatic metastasis, DM: distant metastasis